Niravam

Panic Disorder, Generalized Anxiety Disorder

Treatment

17 Active Studies for Niravam

What is Niravam

Alprazolam

The Generic name of this drug

Treatment Summary

Alprazolam is a medication used to treat anxiety and panic disorders. It should not be taken with medications that contain CYP3A inhibitors. When stopping alprazolam, it is important to do so gradually to avoid withdrawal symptoms. Common side effects of the drug include drowsiness and sedation. Alprazolam has been known to be abused in combination with alcohol, which can lead to coma or death. It was approved by the FDA in 1981.

Alprazolam

is the brand name

image of different drug pills on a surface

Niravam Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Alprazolam

Alprazolam

1981

518

Effectiveness

How Niravam Affects Patients

Alprazolam is a type of medication that works by calming the brain and reducing nerve activity. It must be used carefully because taking it with opioids, such as painkillers, can cause serious side effects and even death. People with breathing problems are especially at risk of these effects. Alprazolam can also be habit-forming, so it needs to be taken as prescribed by a doctor and monitored carefully. Stopping the medication should be done gradually to avoid withdrawal symptoms, which can be severe. Mothers who take alprazolam late in pregnancy may give birth to babies with sedation and withdrawal issues. Alp

How Niravam works in the body

GABA type-A (GABA<sub>A</sub>) receptors help regulate neurotransmission by allowing chloride ions to flow in and out of cells. These receptors are made up of several different subunits, and each has a special binding site for a benzodiazepine drug. When the drug binds to the receptor, it helps open the pore, allowing the chloride ions to flow and produce an inhibitory signal. Different combinations of subunits have slightly different benzodiazepine binding sites that can create different effects. Scientists are still trying to understand how these different sites affect the action of benzodiazepines.

When to interrupt dosage

The proposed quantity of Niravam is subject to the diagnosed condition. The amount of dosage is contingent upon the approach of delivery as outlined in the table below.

Condition

Dosage

Administration

Generalized Anxiety Disorder

, 1.0 mg, 2.0 mg, 3.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Kit, Solution, concentrate, Solution, concentrate - Oral

Panic Disorder

, 1.0 mg, 2.0 mg, 3.0 mg, 0.5 mg, 0.25 mg, 1.0 mg/mL

, Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet - Oral, Tablet, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Kit, Solution, concentrate, Solution, concentrate - Oral

Warnings

Niravam Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Alprazolam may interact with Pulse Frequency

There are 20 known major drug interactions with Niravam.

Common Niravam Drug Interactions

Drug Name

Risk Level

Description

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Alprazolam.

Azelastine

Major

Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Alprazolam.

Carbamazepine

Major

The metabolism of Carbamazepine can be decreased when combined with Alprazolam.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Alprazolam.

Niravam Toxicity & Overdose Risk

Taking too much Alprazolam can cause drowsiness, confusion, clumsiness, unconsciousness, and death. Mixing it with alcohol increases the risk of overdose. If an overdose is suspected, medical professionals should monitor the patient's respiration, pulse, and blood pressure. Treatment may include stomach pumping and intravenous fluids. If the patient's blood pressure is low, they may be given medication to raise it. In some cases, a benzodiazepine receptor antagonist can be used alongside other treatments. The toxic dose of Alprazolam in rats is between 331-2171mg/kg.

image of a doctor in a lab doing drug, clinical research

Niravam Novel Uses: Which Conditions Have a Clinical Trial Featuring Niravam?

A total of 47 active clinical trials are examining the potential of Niravam to manage Generalized Anxiety Disorder.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

7 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Panic Disorder

13 Actively Recruiting

Not Applicable

Niravam Reviews: What are patients saying about Niravam?

5

Patient Review

1/8/2008

Niravam for Panic Disorder

This medicine quickly stopped my panic attack, though I did feel a bit out of it for the rest of the day. A tiny dose (0.25mg) worked within five minutes or so. I only need to use this four to five times per year, which is great.

5

Patient Review

4/25/2011

Niravam for Panic Disorder

I've had generally positive experiences taking this medication. I don't take it on a regular basis, but rather as needed. This has helped me feel better without needing to be constantly reliant on the medication.

5

Patient Review

5/11/2010

Niravam for Anxious

If you suffer from PTSD or anxiety, I cannot recommend this medication enough. It has completely changed my quality of life for the better.

5

Patient Review

9/8/2013

Niravam for Repeated Episodes of Anxiety

I've been taking this for over two decades and it's always helped me when I need it. Though, I have had seizures before when going off of the medication. It's great for my panic attacks and stomach problems.

5

Patient Review

3/19/2008

Niravam for Panic Disorder

Worked very quickly, which was great for me given how high-stress my job is.

5

Patient Review

8/1/2008

Niravam for Anxiousness associated with Depression

After being let go from my job unexpectedly, I was left unable to sleep due to anxiety and racing thoughts. My psychiatrist prescribed Niravam and I found that it worked almost instantly to help me fall asleep at night. During the week I take 1/2 a pill, and on weekends I take a whole pill. I haven't yet taken Niravam during the day, but may soon try it as my current job is very stressful.

5

Patient Review

1/12/2009

Niravam for Repeated Episodes of Anxiety

I had a really great night's sleep after using this treatment.

5

Patient Review

12/28/2009

Niravam for Panic Disorder

This medication is effective in quickly relieving symptoms, but it can be addictive.

5

Patient Review

3/21/2008

Niravam for Anxiousness associated with Depression

This medication typically prevents panic attacks for me that are brought about by TSS or anxiety.

5

Patient Review

4/13/2009

Niravam for Repeated Episodes of Anxiety

This treatment helps me to feel more calm and relaxed very quickly.

4.7

Patient Review

12/8/2008

Niravam for Chronic Trouble Sleeping

I've tried a lot of sleeping aids, and this one is by far the best. It's hard to get from doctors, but it's worth it.

4.7

Patient Review

6/17/2009

Niravam for Panic Disorder

My neurologist prescribed this medication, and it's done wonders for my sleep and panic disorder. I used to only take 2mg, but now 6mg isn't working as well. I want to find a stronger medicine so that eventually I can taper off. It's frustrating when the medicine stops being effective. I've wondered if my pharmacy is selling me expired medications. What should I do?

4.3

Patient Review

7/27/2009

Niravam for Panic Disorder

I've used this medication in the past for panic attacks and it's been really effective. I haven't needed it in a couple years, but I'm currently going through some tough times and feeling like I might need to take it again. I'm breastfeeding, though, so I'm worried about interactions while nursing. Does anyone have any thoughts on this? I just want to be "OK" again without causing any problems with my 5-month-old.

4.3

Patient Review

1/21/2011

Niravam for Anxious

I've just started this treatment, and I have to say that it's been working really well for me. I take it at work, and I definitely feel a lot better now.

4

Patient Review

1/7/2008

Niravam for Panic Disorder

2.3

Patient Review

1/15/2009

Niravam for Panic Disorder

This was the only anxiety medication that worked quickly and efficiently for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about niravam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Niravam discontinued?

"The Niravam brand name has been discontinued as of February 21, 2022. If generic versions of this product have been approved by the FDA, there may be generic equivalents available."

Answered by AI

Is Niravam the same as Xanax?

"Alprazolam is a prescription drug that is available in generic form. The brand names for alprazolam are Xanax, Xanax XR, and Niravam. You need a prescription from your doctor or other health-care professional to obtain this drug."

Answered by AI

Is alprazolam the same as Xanax?

"Medications like Xanax help to control the levels of these chemicals )

The active ingredient in Xanax is called alprazolam. It works by helping to regulate the levels of chemicals in the brain that are responsible for causing anxiety symptoms."

Answered by AI

Is Niravam a controlled substance?

"NIRAVAM belongs to a class of drugs known as benzodiazepines, which have the potential to be addictive and lead to physical and psychological dependence."

Answered by AI

Clinical Trials for Niravam

Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX

Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Image of Baylor College of Medicine in Houston, United States.

Cognitive Behavioral Therapy for Childhood Anxiety and OCD

7 - 17
All Sexes
Houston, TX

Anxiety disorders in children and adolescents are common and confer significant disability. Cognitive behavioral therapy (CBT) is the recommended treatment for youth with anxiety, yet many families cannot access CBT due to cost, practicalities of attending in-person treatment sessions, and a shortage of trained providers, especially in rural areas. To combat these barriers, other treatment methods have been developed. Previous research has shown that family-based, internet-delivered CBT (iCBT) for anxiety and OCD in youth has shown a significant reduction in anxiety symptoms. Parent-coached exposure therapy (PCET) focuses entirely on teaching parents and youth together how to address anxiety through the completion of in-session parent-coached exposures and assigning parent-coached exposure as homework in between sessions. Although both iCBT and PCET show positive results in treating pediatric anxiety in comparison to standard-care CBT, little is known about the comparative efficacy of iCBT and PCET. This research is being done to understand the comparative effectiveness of two different types of cognitive-behavioral therapy (CBT) for treating anxiety or OCD in youth.

Recruiting
Has No Placebo

Baylor College of Medicine

Have you considered Niravam clinical trials?

We made a collection of clinical trials featuring Niravam, we think they might fit your search criteria.
Go to Trials
Image of Bradley Hospital in East Providence, United States.

Cognitive Behavioral Therapy for Pediatric Anxiety

5 - 18
All Sexes
East Providence, RI

The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations. This process of gradually approaching feared situations is called exposure. Although CBT with exposure has the best evidence for treating anxiety disorders, not all children have equal access or respond the same way to CBT. As part of this study, patients will receive weekly CBT treatment sessions involving a combination of weekly visits with an exposure coach and one visit a month with a licensed provider (e.g., psychologist, social worker). This treatment will be delivered using one of three methods: 1) in-person (face-to-face sessions, occurring in the office and the home/community), or 2) telehealth (entirely remote sessions via web-based video conference), or 3) flexible (individualized mix of in-person and/or telehealth sessions). Eligible participants will be randomly assigned to one of these three methods. Results of this study will help determine which treatment method works best for whom. Treatment as described above will occur as part of care at partnering community care sites in Rhode Island. Providers from the following partnering community care sites will make up patient treatment teams: Blackstone Valley Community Health Care, Family Services of Rhode Island, Gateway Healthcare, Newport Mental Health, and Thrive Behavioral Health. The research study is being conducted by the Pediatric Anxiety Research Center at Brown University Health. The research team will conduct the study assessments that patients will be asked to participate in as study participants. Patients will be asked to complete assessments prior to starting treatment, at two time points during treatment, at the end of treatment, and at two timepoints 3 and 6 months following the end of treatment. Participants will be compensated for their time completing research assessments.

Recruiting
Has No Placebo

Bradley Hospital

Image of University of Michigan in Ann Arbor, United States.

Neurofeedback for Anxiety

18 - 24
All Sexes
Ann Arbor, MI

This study seeks to understand emotion regulation in those with young adults with anxiety using real-time functional magnetic resonance imaging neurofeedback, a tool that allows individuals to control brain activity. The goal of this project is to understand how receiving feedback about one's own brain activity relates to emotion regulation ability. This work will help the study team understand the brain areas involved in emotion regulation and could lay the groundwork to test if psychotherapy outcomes can be enhanced using neurofeedback. The study hypotheses include: * Participants receiving veritable-Neurofeedback (NF) will show a greater activation increases in the prefrontal cortex (PFC) compared to sham-NF * Participants receiving veritable-NF will show greater cognitive reappraisal (CR) ability compared to those receiving sham-NF * PFC activation will positively correlate with CR ability

Recruiting
Has No Placebo

University of Michigan

Stefanie Russman Block, Ph.D

Image of UT Southwestern Multispecialty Psychiatry Clinic in Dallas, United States.

Social Therapy for Eating Disorders

18 - 30
All Sexes
Dallas, TX

Social processing and cognition are often altered in patients with eating disorders. The goal of this clinical trial is to assess two different social therapeutic interventions -- one educational, one interactive -- for their effectiveness in improving clinical outcomes in patients with eating disorders. Patients in both interventions will receive education about social function in eating disorders, but those in the interactive treatment group will complete an additional collaborative art task. Participants will: * attend a baseline study visit to complete clinical interviews, cognitive testing, and behavioral tasks * complete a pre-intervention assessment with questionnaires * attend eight sessions of their assigned treatment group over the course of 12 weeks * complete three virtual follow-up assessments 4, 8, and 12 months from their baseline * attend a final study visit to repeat some clinical interviews, cognitive testing, and behavioral tasks Researchers will compare changes in eating disorder, mood, and anxiety symptoms as well as test results from baseline and final study visits for each group to see if * patients can be treated effectively with education alone or if an interactive group component produces additional benefits * cognitive and behavioral task performance are associated with recovery or illness state.

Recruiting
Has No Placebo

UT Southwestern Multispecialty Psychiatry Clinic

Carrie J McAdams, MD PhD

Image of Baylor College of Medicine in Houston, United States.

Family-Based Behavioral Therapy for Childhood Anxiety and OCD

7 - 13
All Sexes
Houston, TX

Anxiety and obsessive-compulsive disorders are among the most common in children. Although cognitive behavioral therapy (CBT) is an effective and evidence-based treatment for such disorders, access to CBT is often limited. Family-based and internet-delivered therapy is one method to increase access to care. The purpose of this project is to evaluate the comparative efficacy and treatment mechanisms of two lower-intensity but effective treatments for families of children with anxiety or obsessive compulsive disorder (OCD) via telehealth compared to an adapted Relaxation and Mentorship Training (RMT) intervention involving breathing exercises with a therapist.

Waitlist Available
Has No Placebo

Baylor College of Medicine

Have you considered Niravam clinical trials?

We made a collection of clinical trials featuring Niravam, we think they might fit your search criteria.
Go to Trials
Image of Université de Sherbrooke in Sherbrooke, Canada.

Group Self-Management Support for Anxiety Disorders

18+
All Sexes
Sherbrooke, Canada

Background. Self-management support is a complementary approach to treatment that aims to educate participants on the nature of anxiety and to improve their strategies to manage symptoms and well-being, thus presenting the potential to enhance recovery, improve outcomes, reduce recurrence rates and lower health care costs. There is limited evidence to support the effectiveness of group self-management support for anxiety disorders in community-based care. Objectives. This study aims at examining the effectiveness of a virtual group self-management support program (SMS) for anxiety disorders as an add-on to treatment-as-usual (TAU) in community-based care settings. We will also assess the incremental cost/effectiveness ratio and the implementability of the intervention. Methods. The trial is a pragmatic randomized controlled trial with a pre-treatment, post-treatment (4-month post-randomization), and follow-ups at 8, 12 and 24-months. Intervention. The experimental condition will consist of a 10-week SMS program for anxiety disorders in addition to TAU. The control condition will receive TAU without restrictions for anxiety disorders. Inclusion criteria will comprise being 18 years old or older, French-speaking, and presenting symptoms of anxiety disorders based on self-reported validated assessment scales. Patients will be recruited in the province of Quebec (Canada). Outcome measures: The primary outcome measure is the Beck Anxiety Inventory (BAI). The secondary outcome measures include self-reported instruments for anxiety and depressive symptoms, recovery, self-management, quality of life, and service utilisation. Statistical analysis: Intention-to-treat analysis. A mixed effects regression model will be used to account for between and within-subject variations in the analysis of the longitudinal effects of the intervention. Expected outcomes. The rigorous evaluation of the SMS intervention in the real world will provide information to decision makers, health care managers, clinicians and patients regarding the added value of group SMS for patients with anxiety disorders. Widespread implementation of this intervention could lead to more efficient mental health care services, to better long-term outcomes and to a significant reduction in the extensive social and economic burden of anxiety disorders.

Waitlist Available
Has No Placebo

Université de Sherbrooke

Pasquale Roberge, Ph.D.

Have you considered Niravam clinical trials?

We made a collection of clinical trials featuring Niravam, we think they might fit your search criteria.
Go to Trials